| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sonia Alavi, Mohammad A Mahjoob, Azadeh Haeri, Farshad H Shirazi, Zahra Abbasian, Simin Dadashzade. Multivesicular liposomal depot system for sustained delivery of risperidone: development, characterization, and toxicity assessment. Drug development and industrial pharmacy. 2021-10-15. PMID:34620021. |
considering the limitations of conventional risperidone (rsp) therapies, the present research characterizes the usefulness of multivesicular liposomes (mvls) as an efficient controlled-release carrier for this widely used antipsychotic drug, to be employed for the treatment of schizophrenia. |
2021-10-15 |
2023-08-13 |
Not clear |
| Wenwen Gao, Guangfei Li, Xiaowei Han, Zeyu Song, Shuai Zhao, Feiyi Sun, Hong Ma, Ailing Cui, Yige Wang, Xiuxiu Liu, Yue Chen, Lu Zhang, Guolin Ma, Xiaoying Tan. Regional brain network and behavioral alterations in EGR3 gene transfected rat model of schizophrenia. Brain imaging and behavior. vol 15. issue 5. 2021-10-12. PMID:33723811. |
this study aimed to investigate the behavioral and cerebral alterations of the schizophrenic model rats and the risperidone effects. twenty-six rats were divided into 3 groups: schizophrenia model group (e group), risperidone treatment group (t group), and healthy control group (h group). |
2021-10-12 |
2023-08-13 |
rat |
| Wenwen Gao, Guangfei Li, Xiaowei Han, Zeyu Song, Shuai Zhao, Feiyi Sun, Hong Ma, Ailing Cui, Yige Wang, Xiuxiu Liu, Yue Chen, Lu Zhang, Guolin Ma, Xiaoying Tan. Regional brain network and behavioral alterations in EGR3 gene transfected rat model of schizophrenia. Brain imaging and behavior. vol 15. issue 5. 2021-10-12. PMID:33723811. |
this study lends support for future research on the pathology of schizophrenia and provides new insights on the role of risperidone in schizophrenia. |
2021-10-12 |
2023-08-13 |
rat |
| Jiahong Liu, Pingping Wang, Leilei Sun, Xiaoni Guan, Meihong Xiu, Xiangyang Zhan. The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study. Translational psychiatry. vol 11. issue 1. 2021-10-11. PMID:34482368. |
furthermore, the negative association between weight gain and increased bdnf levels during risperidone treatment in anfe schizophrenia depends on the bdnf val66met polymorphism. |
2021-10-11 |
2023-08-13 |
Not clear |
| John M Kane, Suresh Durgam, Andrew Satlin, Kimberly E Vanover, Richard Chen, Robert Davis, Sharon Mate. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. International clinical psychopharmacology. vol 36. issue 5. 2021-10-04. PMID:34054112. |
the pooled population comprised 1073 patients with an acute exacerbation of schizophrenia randomized to placebo (n = 412), lumateperone 42 mg (n = 406) or risperidone 4 mg (n = 255). |
2021-10-04 |
2023-08-13 |
Not clear |
| Anne Le Moigne, Maurizio Fava, John Csernansky, John W Newcomer, James Graha. Reanalysis of a Phase 3 Trial of a Monthly Extended-Release Risperidone Injection for the Treatment of Acute Schizophrenia. Journal of clinical psychopharmacology. vol 41. issue 1. 2021-10-01. PMID:33208710. |
reanalysis of a phase 3 trial of a monthly extended-release risperidone injection for the treatment of acute schizophrenia. |
2021-10-01 |
2023-08-13 |
Not clear |
| Minami Tasaki, Norio Yasui-Furukori, Saaya Yokoyama, Masataka Shinozaki, Norio Sugawara, Kazutaka Shimod. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacology reports. vol 41. issue 3. 2021-09-21. PMID:34189861. |
hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. |
2021-09-21 |
2023-08-13 |
Not clear |
| Haixia Liu, Rui Yu, Yanan Gao, Xirong Li, Xiaoni Guan, Kosten Thomas, Meihong Xiu, Xiangyang Zhan. Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: a prospective longitudinal study. Current neuropharmacology. 2021-09-21. PMID:34544343. |
antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: a prospective longitudinal study. |
2021-09-21 |
2023-08-13 |
cat |
| Yun-Shuang Fan, Haoru Li, Jing Guo, Yajing Pang, Liang Li, Maolin Hu, Meiling Li, Chong Wang, Wei Sheng, Hesheng Liu, Qing Gao, Xiaogang Chen, Xiaofen Zong, Huafu Che. Tracking Positive and Negative Symptom Improvement in First-Episode Schizophrenia Treated with Risperidone Using Individual-Level Functional Connectivity. Brain connectivity. 2021-09-14. PMID:34210149. |
tracking positive and negative symptom improvement in first-episode schizophrenia treated with risperidone using individual-level functional connectivity. |
2021-09-14 |
2023-08-13 |
Not clear |
| Jan Kucera, Katerina Horska, Pavel Hruska, Daniela Kuruczova, Vincenzo Micale, Jana Ruda-Kucerova, Julie Bienertova-Vask. Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue. Progress in neuro-psychopharmacology & biological psychiatry. vol 108. 2021-09-02. PMID:33152383. |
we employed mass spectrometry-based untargeted proteomics to assess the effect of chronic olanzapine, risperidone, and haloperidol treatment in visceral adipose tissue of prenatally methylazoxymethanol (mam) acetate exposed rats, a well-validated neurodevelopmental animal model of schizophrenia. |
2021-09-02 |
2023-08-13 |
rat |
| Elisabetta Maffioletti, Paolo Valsecchi, Alessandra Minelli, Chiara Magri, Cristian Bonvicini, Stefano Barlati, Emilio Sacchetti, Antonio Vita, Massimo Gennarell. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug development research. vol 81. issue 6. 2021-09-01. PMID:32462699. |
association study between htr2a rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. |
2021-09-01 |
2023-08-13 |
Not clear |
| Elisabetta Maffioletti, Paolo Valsecchi, Alessandra Minelli, Chiara Magri, Cristian Bonvicini, Stefano Barlati, Emilio Sacchetti, Antonio Vita, Massimo Gennarell. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug development research. vol 81. issue 6. 2021-09-01. PMID:32462699. |
with the aim to test for the first time the application of a dimensional approach for the evaluation of early response, we carried out a genetic association study between rs6313 and antipsychotic response in two groups of schizophrenia patients in monotherapy with risperidone (n = 121) and olanzapine (n = 100). |
2021-09-01 |
2023-08-13 |
Not clear |
| Zhi Wei Wu, Hui Shi, Da Chun Chen, Song Chen, Mei Hong Xiu, Xiang Yang Zhan. BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: A prospective 12-week longitudinal study. Psychoneuroendocrinology. vol 122. 2021-08-30. PMID:33049658. |
the study aimed to investigate the effect of risperidone monotherapy on cognitive impairment in drug-naïve first-episode (dnfe) patients with schizophrenia and whether bdnf levels were correlated to the improvement of cognition. |
2021-08-30 |
2023-08-13 |
Not clear |
| Zhi Wei Wu, Hui Shi, Da Chun Chen, Song Chen, Mei Hong Xiu, Xiang Yang Zhan. BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: A prospective 12-week longitudinal study. Psychoneuroendocrinology. vol 122. 2021-08-30. PMID:33049658. |
our result suggests risperidone treatment can partially improve certain domains of the cognitive impairment and baseline bdnf levels are related to cognitive response to risperidone in dnfe patients with schizophrenia. |
2021-08-30 |
2023-08-13 |
Not clear |
| Zeyuan Wang, Josiah Poon, Shuze Wang, Shiding Sun, Simon Poo. A novel method for clinical risk prediction with low-quality data. Artificial intelligence in medicine. vol 114. 2021-08-18. PMID:33875163. |
we evaluate it on three suitable data sets from real-world settings with different clinical risk prediction tasks: adverse drug reaction of risperidone, schizophrenia relapse, and invasive fungi infection, respectively. |
2021-08-18 |
2023-08-13 |
Not clear |
| Paula Soria-Chacartegui, Gonzalo Villapalos-García, Pablo Zubiaur, Francisco Abad-Santos, Dora Kolle. Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Frontiers in pharmacology. vol 12. 2021-08-03. PMID:34335273. |
olanzapine, aripiprazole and risperidone are atypical antipsychotics or neuroleptics widely used for schizophrenia treatment. |
2021-08-03 |
2023-08-13 |
Not clear |
| Dachun Chen, Hongna Li, Qing Zhao, Jiaqi Song, Chen Lin, Jianjin Y. Effect of risperidone treatment on insulin-like growth factor-1 and interleukin-17 in drug naïve first-episode schizophrenia. Psychiatry research. vol 297. 2021-08-02. PMID:33503523. |
effect of risperidone treatment on insulin-like growth factor-1 and interleukin-17 in drug naïve first-episode schizophrenia. |
2021-08-02 |
2023-08-13 |
human |
| John B Edwards, Andrew Satlin, Suresh Durgam, Robert E Davis, Richard Chen, Sharon Mates, Christoph U Correl. Cardiometabolic Safety of Lumateperone (ITI-007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127092. |
this post hoc analysis of 2 randomized, double-blind, placebo-controlled studies of patients with an acute exacerbation of schizophrenia compared rates of metsy with lumateperone and risperidone. |
2021-07-23 |
2023-08-13 |
Not clear |
| Zebun Nisa, Asia Naz, Syed Imran Ali, Mehwish Rizvi, Muhammad Shahid Iqbal, Saira Shahnaz, Ale Zehra, Samina Sheikh, Shaheen Perveen, Hira Arif, Saba Inayat, Muhammad Mustafa Swaleh, Sadia Suri Kashif, Mehwish Murad Ali, Hira Akhta. Determining the release kinetics of risperidone controlled release matrices to treat schizophrenia. Pakistan journal of pharmaceutical sciences. vol 34. issue 2(Supplementary). 2021-07-19. PMID:34275799. |
determining the release kinetics of risperidone controlled release matrices to treat schizophrenia. |
2021-07-19 |
2023-08-13 |
Not clear |
| Zebun Nisa, Asia Naz, Syed Imran Ali, Mehwish Rizvi, Muhammad Shahid Iqbal, Saira Shahnaz, Ale Zehra, Samina Sheikh, Shaheen Perveen, Hira Arif, Saba Inayat, Muhammad Mustafa Swaleh, Sadia Suri Kashif, Mehwish Murad Ali, Hira Akhta. Determining the release kinetics of risperidone controlled release matrices to treat schizophrenia. Pakistan journal of pharmaceutical sciences. vol 34. issue 2(Supplementary). 2021-07-19. PMID:34275799. |
the once daily formulation of risperidone could be beneficial for schizophrenia patients and their caregivers and will improve patient compliance. |
2021-07-19 |
2023-08-13 |
Not clear |